Literature DB >> 24030384

DNA methylation of Runx1 regulatory regions correlates with transition from primitive to definitive hematopoietic potential in vitro and in vivo.

Beau R Webber1, Michelina Iacovino, Si Ho Choi, Jakub Tolar, Michael Kyba, Bruce R Blazar.   

Abstract

The transcription factor Runx1 (AML1) is a central regulator of hematopoiesis and is required for the formation of definitive hematopoietic stem cells (HSCs). Runx1 is alternatively expressed from two promoters: the proximal (P2) prevails during primitive hematopoiesis, while the distal (P1) dominates in definitive HSCs. Although some transcription factor binding sites and cis-regulatory elements have been identified, a mechanistic explanation for the alternative promoter usage remains elusive. We investigated DNA methylation of known Runx1 cis-elements at stages of hematopoietic development in vivo and during differentiation of murine embryonic stem cells (ESCs) in vitro. In vivo, we find loss of methylation correlated with the primitive to definitive transition at the P1 promoter. In vitro, hypomethylation, acquisition of active chromatin modifications, and increased transcriptional activity at P1 are promoted by direct interaction with HOXB4, a transcription factor that confers definitive repopulation status on primitive hematopoietic progenitors. These data demonstrate a novel role for DNA methylation in the alternative promoter usage at the Runx1 locus and identify HOXB4 as a direct activator of the P1 promoter. This epigenetic signature should serve as a novel biomarker of HSC potential in vivo, and during ESC differentiation in vitro.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24030384      PMCID: PMC3811172          DOI: 10.1182/blood-2013-03-489369

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  46 in total

1.  CD41 expression defines the onset of primitive and definitive hematopoiesis in the murine embryo.

Authors:  Michael J Ferkowicz; Mark Starr; Xiaodong Xie; Weiming Li; Scott A Johnson; William C Shelley; Paul R Morrison; Mervin C Yoder
Journal:  Development       Date:  2003-09       Impact factor: 6.868

2.  The mouse Runx1 +23 hematopoietic stem cell enhancer confers hematopoietic specificity to both Runx1 promoters.

Authors:  Thomas Bee; Emma L K Ashley; Sorrel R B Bickley; Andrew Jarratt; Pik-Shan Li; Jackie Sloane-Stanley; Berthold Göttgens; Marella F T R de Bruijn
Journal:  Blood       Date:  2009-03-25       Impact factor: 22.113

3.  Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells.

Authors:  Michael Weber; Jonathan J Davies; David Wittig; Edward J Oakeley; Michael Haase; Wan L Lam; Dirk Schübeler
Journal:  Nat Genet       Date:  2005-07-10       Impact factor: 38.330

4.  Haploinsufficiency of AML1 affects the temporal and spatial generation of hematopoietic stem cells in the mouse embryo.

Authors:  Z Cai; M de Bruijn; X Ma; B Dortland; T Luteijn; R J Downing; E Dzierzak
Journal:  Immunity       Date:  2000-10       Impact factor: 31.745

5.  Architecture and anatomy of the genomic locus encoding the human leukemia-associated transcription factor RUNX1/AML1.

Authors:  D Levanon; G Glusman; T Bangsow; E Ben-Asher; D A Male; N Avidan; C Bangsow; M Hattori; T D Taylor; S Taudien; K Blechschmidt; N Shimizu; A Rosenthal; Y Sakaki; D Lancet; Y Groner
Journal:  Gene       Date:  2001-01-10       Impact factor: 3.688

6.  Genome-scale DNA methylation maps of pluripotent and differentiated cells.

Authors:  Alexander Meissner; Tarjei S Mikkelsen; Hongcang Gu; Marius Wernig; Jacob Hanna; Andrey Sivachenko; Xiaolan Zhang; Bradley E Bernstein; Chad Nusbaum; David B Jaffe; Andreas Gnirke; Rudolf Jaenisch; Eric S Lander
Journal:  Nature       Date:  2008-07-06       Impact factor: 49.962

7.  The differential activities of Runx1 promoters define milestones during embryonic hematopoiesis.

Authors:  Patrycja Sroczynska; Christophe Lancrin; Valerie Kouskoff; Georges Lacaud
Journal:  Blood       Date:  2009-10-26       Impact factor: 22.113

8.  Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming.

Authors:  Jie Deng; Robert Shoemaker; Bin Xie; Athurva Gore; Emily M LeProust; Jessica Antosiewicz-Bourget; Dieter Egli; Nimet Maherali; In-Hyun Park; Junying Yu; George Q Daley; Kevin Eggan; Konrad Hochedlinger; James Thomson; Wei Wang; Yuan Gao; Kun Zhang
Journal:  Nat Biotechnol       Date:  2009-03-29       Impact factor: 54.908

9.  Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter.

Authors:  Michael J Chen; Tomomasa Yokomizo; Brandon M Zeigler; Elaine Dzierzak; Nancy A Speck
Journal:  Nature       Date:  2009-01-07       Impact factor: 49.962

10.  Runx1-mediated hematopoietic stem-cell emergence is controlled by a Gata/Ets/SCL-regulated enhancer.

Authors:  Wade T Nottingham; Andrew Jarratt; Matthew Burgess; Caroline L Speck; Jan-Fang Cheng; Shyam Prabhakar; Eddy M Rubin; Pik-Shan Li; Jackie Sloane-Stanley; John Kong-A-San; Marella F T R de Bruijn
Journal:  Blood       Date:  2007-09-06       Impact factor: 22.113

View more
  12 in total

1.  HOXB4 Increases Runx1 Expression to Promote the de novo Formation of Multipotent Hematopoietic Cells.

Authors:  Nadine Teichweyde; Peter A Horn; Hannes Klump
Journal:  Transfus Med Hemother       Date:  2017-05-19       Impact factor: 3.747

2.  Chromatin and Transcriptional Analysis of Mesoderm Progenitor Cells Identifies HOPX as a Regulator of Primitive Hematopoiesis.

Authors:  Nathan J Palpant; Yuliang Wang; Brandon Hadland; Rebecca J Zaunbrecher; Meredith Redd; Daniel Jones; Lil Pabon; Rajan Jain; Jonathan Epstein; Walter L Ruzzo; Ying Zheng; Irwin Bernstein; Adam Margolin; Charles E Murry
Journal:  Cell Rep       Date:  2017-08-15       Impact factor: 9.423

3.  Early life lead exposure causes gender-specific changes in the DNA methylation profile of DNA extracted from dried blood spots.

Authors:  Arko Sen; Nicole Heredia; Marie-Claude Senut; Matthew Hess; Susan Land; Wen Qu; Kurt Hollacher; Mary O Dereski; Douglas M Ruden
Journal:  Epigenomics       Date:  2015       Impact factor: 4.778

Review 4.  The RUNX family: developmental regulators in cancer.

Authors:  Yoshiaki Ito; Suk-Chul Bae; Linda Shyue Huey Chuang
Journal:  Nat Rev Cancer       Date:  2015-01-16       Impact factor: 60.716

5.  Profiling the epigenetic interplay of lncRNA RUNXOR and oncogenic RUNX1 in breast cancer cells by gene in situ cis-activation.

Authors:  Yuanyuan Nie; Lei Zhou; Hong Wang; Naifei Chen; Lin Jia; Cong Wang; Yichen Wang; Jingcheng Chen; Xue Wen; Chao Niu; Hui Li; Rui Guo; Songling Zhang; Jiuwei Cui; Andrew R Hoffman; Ji-Fan Hu; Wei Li
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

Review 6.  Hematopoiesis: from start to immune reconstitution potential.

Authors:  Haydn C-Y Liang; Juan Carlos Zúñiga-Pflücker
Journal:  Stem Cell Res Ther       Date:  2015-04-11       Impact factor: 6.832

7.  Whole-transcriptome splicing profiling of E7.5 mouse primary germ layers reveals frequent alternative promoter usage during mouse early embryogenesis.

Authors:  Xukun Lu; Zhen-Ao Zhao; Xiaoqing Wang; Xiaoxin Zhang; Yanhua Zhai; Wenbo Deng; Zhaohong Yi; Lei Li
Journal:  Biol Open       Date:  2018-03-28       Impact factor: 2.422

8.  The transcription factor Zfp90 regulates the self-renewal and differentiation of hematopoietic stem cells.

Authors:  Ting Liu; Wei-Xia Kong; Xiao-Yi Tang; Man Xu; Qing-Han Wang; Bin Zhang; Liang-Ding Hu; Hu Chen
Journal:  Cell Death Dis       Date:  2018-06-07       Impact factor: 8.469

9.  HOXB4 Promotes Hemogenic Endothelium Formation without Perturbing Endothelial Cell Development.

Authors:  Nadine Teichweyde; Lara Kasperidus; Sebastian Carotta; Valerie Kouskoff; Georges Lacaud; Peter A Horn; Stefan Heinrichs; Hannes Klump
Journal:  Stem Cell Reports       Date:  2018-02-15       Impact factor: 7.765

Review 10.  RUNX family: Oncogenes or tumor suppressors (Review).

Authors:  Beatriz Andrea Otálora-Otálora; Berta Henríquez; Liliana López-Kleine; Adriana Rojas
Journal:  Oncol Rep       Date:  2019-05-06       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.